We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Representatives from several U.S. law enforcement agencies said granting them the authority to destroy drugs illegally shipped into the U.S. at the point of import would go a long way toward lightening the load of policing illicit internet drug purchases.
What some Democrats say is GOP duplicity and what some Republicans say are unreasonable demands from Democrats appear to be stalling some spending, tax and regulatory bills that could significantly affect the pharmaceutical industry.
The FDA’s director of pharmacy affairs is warning that, if a provision passed by the House barring the agency from spending federal money to block FDA-approved drug importation were to take effect, the doors might be opened to drug counterfeiters.
Spending, tax and regulatory bills that could significantly affect the pharmaceutical industry are being delayed by what some Democrats say is GOP duplicity and what some Republicans say are unreasonable demands from Democrats.
The National Institutes of Health (NIH) will undergo a top-to-bottom vetting by the House Energy and Commerce Committee this year as part of the panel’s effort to devise a bipartisan reauthorization package, a spokesman for the committee said.
Manufacturers of digoxin elixirs can continue marketing them without agency-approved new drug applications for an additional six months to ensure continued availability of the products, the FDA announced.
A key Senate lawmaker expects a recently passed bill to be addressed by a joint House-Senate conference committee immediately after the July 4 recess so as not to disrupt the plans of businesses that are counting on a research and development (R&D) tax-credit provision in the legislation.
The House passed sweeping legislation last week that would provide tax relief to all U.S. corporations — including drug manufacturers — that do business abroad.
Senate GOP leadership has given Sen. Richard Durbin (D-Ill.) assurance that there will be action this year on his amendment requiring manufacturers who sell dietary supplements containing stimulants to turn over to the FDA reports of serious adverse events (AEs).
The flow of illegally imported Rx drugs into the U.S. will increase if drug importation bills now being considered in Congress do not include a number of safeguards and adequate financial resources for regulatory bodies, participants at a National Association of Boards of Pharmacy (NABP) news conference said June 23.